NAOV vs. BBLG, HSCS, POAI, GLMD, ACON, WINT, ALLR, ISPC, DYNT, and QLGN
Should you be buying NanoVibronix stock or one of its competitors? The main competitors of NanoVibronix include Bone Biologics (BBLG), Heart Test Laboratories (HSCS), Predictive Oncology (POAI), Galmed Pharmaceuticals (GLMD), Aclarion (ACON), Windtree Therapeutics (WINT), Allarity Therapeutics (ALLR), iSpecimen (ISPC), Dynatronics (DYNT), and Qualigen Therapeutics (QLGN). These companies are all part of the "medical" sector.
NanoVibronix (NASDAQ:NAOV) and Bone Biologics (NASDAQ:BBLG) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, community ranking, dividends, risk and profitability.
NanoVibronix has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Comparatively, Bone Biologics has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500.
In the previous week, NanoVibronix had 1 more articles in the media than Bone Biologics. MarketBeat recorded 4 mentions for NanoVibronix and 3 mentions for Bone Biologics. Bone Biologics' average media sentiment score of 1.46 beat NanoVibronix's score of 0.06 indicating that Bone Biologics is being referred to more favorably in the news media.
NanoVibronix received 71 more outperform votes than Bone Biologics when rated by MarketBeat users.
16.4% of NanoVibronix shares are owned by institutional investors. Comparatively, 34.3% of Bone Biologics shares are owned by institutional investors. 3.6% of NanoVibronix shares are owned by insiders. Comparatively, 13.0% of Bone Biologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
NanoVibronix has higher revenue and earnings than Bone Biologics.
Bone Biologics has a net margin of 0.00% compared to NanoVibronix's net margin of -112.35%. NanoVibronix's return on equity of -95.96% beat Bone Biologics' return on equity.
Summary
NanoVibronix beats Bone Biologics on 7 of the 11 factors compared between the two stocks.
Get NanoVibronix News Delivered to You Automatically
Sign up to receive the latest news and ratings for NAOV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NAOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NanoVibronix Competitors List
Related Companies and Tools
